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Abstract 
Objectives. To examine how comorbidities cluster in axial spondyloarthritis (axSpA) and 
whether these clusters are associated with quality of life, global health and other outcome 
measures. 
Methods. We conducted a cross-sectional study of consecutive patients meeting ASAS criteria 
for axSpA in Liverpool, UK. Outcome measures included quality of life (EQ5D), global health and 
disease activity (BASDAI). We used hierarchical cluster analysis to group patients according to 38 
pre-specified comorbidities. In multivariable linear models, the associations between distinct 
comorbidity clusters and each outcome measure were compared, using axSpA patients with no 
comorbidities as the reference group. Analyses were adjusted for age, gender, symptom 
duration, BMI, deprivation, NSAID-use and smoking. 
Results. We studied 419 patients (69% male, mean age 46 years). 255 patients (61%) had at 
least one comorbidity, among whom the median number was 1 (range 1 to 6). Common 
comorbidities were hypertension (19%) and depression (16%). Of 15 clusters identified, the 
most prevalent clusters were 1) hypertension-coronary heart disease and 2) depression-anxiety. 
Compared to patients with no comorbidities, the fibromyalgia-irritable bowel syndrome cluster 
was associated with an adverse patient-reported outcome measures; these patients reported 
1.5-unit poorer global health (95%CI 0.01, 2.9), reduced quality of life (0.25-unit lower EQ5D; 
95%CI -0.37, -0.12) and 1.8-unit higher BASDAI (95% CI 0.4, 3.3). Similar effect estimates were 
found for patient in the depression-anxiety cluster. 
Conclusion. Comorbidity is common among axSpA patients. The two most common 
comorbidities were hypertension and depression. Patients in the depression-anxiety and 
fibromyalgia-IBS clusters reported poorer health and increased axSpA severity. 
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Key messages: 
1. Comorbidity is common among axial spondyloarthritis patients. 
2. The most common comorbidity-clusters were those dominated by hypertension-coronary 
artery disease and depression-anxiety. 
3. The depression-anxiety and fibromyalgia-irritable bowel syndrome clusters were associated 
with poorer patient-reported outcome measures. 
 
Introduction 
As life expectancy increases in many countries, healthcare professionals are seeing a growing 
number of patients living with multiple coexisting conditions. Healthcare delivery and clinical 
research have traditionally focused on individual diseases, but the paradigm is shifting towards 
holistic care, aligning healthcare services more closely with patient-needs [1–3]. Although the 
terms are often used interchangeably, “comorbidity” refers to coexisting morbidities in addition 
to an index disease, whereas “multimorbidity” is a more patient-centred concept that refers to 
the combination of any two chronic conditions [1].  
Comorbidity is common among patients with chronic rheumatic diseases due to shared risk 
factors and sequelae of systemic inflammation. In rheumatoid arthritis (RA), increasing 
morbidity burden is associated with poorer quality of life, function and treatment response [4–
6]. Comorbidity profiles are likely to differ in axSpA patients given their different demographic, 
younger age of onset and lower levels of systemic inflammation, but detailed descriptions are 
lacking. 
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Comorbidities have commonly been studied using count-based indices [7,8] that assign 
importance to individual conditions according to their impact on mortality [9,10]. However, 
health-related quality of life and global health are equally important outcomes in chronic 
diseases; these measures are well-aligned with the model of patient-centred care. Count-based 
approaches also do not account for relationships between morbidities, for instance between 
hypertension and cardiovascular disease. Cluster analysis is a statistical technique that allows 
assessment of which comorbidities commonly co-occur, and facilitates identification of patient-
groups with specific clusters of disease most associated with poor quality of life, who may 
benefit from additional intervention. 
The aim of this cross-sectional study was to 1) describe axSpA patients according to clusters of 
comorbidities and 2) assess whether these clusters are associated with quality of life, global 
health and other disease-specific outcome measures. 
Methods 
Study population  
We conducted a cross-sectional study of consecutive axSpA patients attending a tertiary referral 
service in Liverpool, UK, between 2010 and 2017. Patients were included if they fulfilled the 
Assessment of Spondyloarthritis international Society (ASAS) criteria for axSpA [11]. The time at 
which all variables of interest were collected - the baseline - was defined as each patient’s first 
clinical assessment at this referral centre, which was not necessarily the time of diagnosis. Data 
were retrospectively collected through review of medical records, including: age, gender, 
symptom duration, meeting modified New York criteria for ankylosing spondylitis (AS) [12], HLA-
B27 status, peripheral joint involvement, uveitis, psoriasis, inflammatory bowel disease (IBD), 
body mass index (BMI), smoking status and medications. Socioeconomic status was measured 
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using a post-code-derived index of multiple deprivation; decile 1 relates to the top 10% most 
deprived areas and decile 10 the most affluent [13].  
Comorbidity 
We selected comorbidities according to previous work conducted in the UK population; this 
study included 40 chronic diseases based on recommendations for measurement of multiple 
chronic diseases, and on diseases considered important by the National Health Service [3]. 
Extra-articular manifestations of axSpA (uveitis, psoriasis and IBD) were considered as disease 
features rather than separate comorbidities, given that they share pathogenesis with, aid 
diagnosis of, and influence treatment for, axSpA [14,15]. We also excluded inflammatory 
polyarthropathy/connective tissue disease, changed “painful conditions” to fibromyalgia, and 
added osteoporosis because of its importance in chronic rheumatic musculoskeletal diseases 
[6]. Two clinicians independently reviewed clinical notes, medications, and correspondence 
from primary and secondary care physicians to determine the presence or absence of these 38 
conditions for every patient. Some conditions (e.g. asthma and epilepsy) were only counted if 
currently treated, while other conditions were assumed to be present if indicative medications 
were used, for example diabetes mellitus (insulin or oral hypoglycaemics) and hypertension 
(antihypertensives without kidney or heart disease). A list of definitions used for each condition 
is provided in Supplementary Table 1. 
Outcome measures 
Primary outcome measures of interest were quality of life and global health. Quality of life was 
measured using the 3-level version of EuroQol (EQ5D-3L); this index assesses 5 dimensions 
(mobility, self-care, usual activities, pain/discomfort, anxiety/depression) to generate a score 
anchored at 1 for ‘best health state’, and 0 for ‘worst health state equalling death’ [16]. Global 
health was assessed using the question “how would you describe your general state of health 
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today?” on a visual analogue scale (VAS), with 0 being best and 10 being worst. Other variables 
included ESR, CRP, fatigue (“How would you describe the level of fatigue/tiredness you have 
experienced?” VAS with 0 being no fatigue and 10 being worst ever experienced), and axSpA-
specific outcome measures such as the Bath AS Disease Activity Index (BASDAI), spinal pain VAS 
and Bath AS Functional Index (BASFI).  
Statistical analysis 
Patient and disease characteristics were compared according to whether patients had isolated 
axSpA, or axSpA with at least one comorbidity. We then used agglomerative hierarchical cluster 
analysis to classify individuals into groups based on comorbidities; this is a commonly used 
method suited to binary variables [17,18]. The algorithm starts with individual patients and 
successively clusters them until the final group contains all patients. We used the Jaccard 
similarity coefficient as a measure of distance between binary variables, and average linkage, to 
define the average distance between data points in separate clusters [19]. All prevalent 
conditions in this cohort were included in the cluster analysis. The optimum number of clusters 
was determined by the pseudo-F statistic [20].  
Patient characteristics of each comorbidity cluster were described. We then compared each 
cluster to patients with isolated axSpA (i.e. no comorbidity) using multivariable linear models for 
each outcome measure as the dependent variable, and cluster as a dummy independent 
variable. Small clusters (less than 5 patients) were combined into one cluster for regression 
modelling. All models were adjusted for age, gender, symptom duration, smoking status, BMI, 
social deprivation and current NSAID-use. ESR and CRP were log-transformed prior to 
regression. We did not correct for multiple comparisons, since the outcome variables were not 
independent. 
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Primary analyses were performed with no imputation for missing data; we additionally 
performed sensitivity analyses using multiple imputation by chained equations [21]. We also 
repeated the cluster analysis only using comorbidities that were prevalent in at least two 
patients to test the stability of cluster formation. Statistical analyses were performed using Stata 
version 13.  
Results 
The study included 421 patients with established axSpA. Sufficient clinical data were available 
for 419 patients. The cohort was predominantly male (69%) with a mean age of 45.5 years 
(SD±14.3). 82% fulfilled the modified New York criteria for AS. HLA-B27 was available in 269 and 
of these 59% were positive. Two patients were prescribed TNF inhibitors and 17% were 
currently using NSAIDs at baseline. 
At least one comorbidity was seen in 255 (61%) axSpA patients, among whom the median 
number of conditions was 1 (range 1 to 6; histogram shown in supplementary figure 1). 
Compared to those with isolated axSpA, patients with comorbidity were older (48.9 vs 40.4 
years, P<0.001) and reported impaired quality of life (P<0.001), global health (P=0.005), fatigue 
(P=0.021), BASDAI (P=0.011), spinal pain (P=0.029) and BASFI (P<0.001), but did not have 
significantly different ESR or CRP levels (table 1). The most common comorbidities were 
hypertension (19%), depression (16%) and dyspepsia (11%) (prevalence of each comorbidity is 
shown in supplementary table 2). 
Cluster analysis 
No patients had dementia, hearing loss, bronchiectasis or anorexia. The diagram from cluster 
analysis of the remaining 34 conditions is shown in figure 1. The pseudo-F statistic identified 15 
as the optimum number of clusters (dotted horizontal line in figure 1), labelled in numerical 
order from left to right. Clustering generally occurred at low levels of similarity. 
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Figure 1. Diagram (“dendrogram”) from cluster analysis of 419 patients and 34 
comorbidities. Zero on the y-axis indicates no similarity between clusters. From the 
bottom, clusters progressive joined (at levels of similarity shown at their union) until a 
single cluster is formed at the top. The pseudo-F statistic determined the optimum 
number of clusters, indicated by where the dotted horizontal line intersects with the 
branches. Clusters are labelled 1 to 15 from left to right based on the dominant 
comorbidity in the cluster (C1: isolated axSpA, C2: dyspepsia, C3: depression-anxiety, 
C4: fibromyalgia-irritable bowel syndrome, C5: anxiety, C6: hypertension, C7: 
osteoporosis-alcohol problems, C8: thyroid disorders, C9: other substance misuse, C10: 
asthma, C11: atrial fibrillation, C12: chronic sinusitis, C13: blind or low vision, C14: 
multiple sclerosis, C15: learning disability.) 
 
Six clusters were formed at near-zero similarity, indicating relative distinctness. Cluster 1 (C1, 
n=164) consisted of patients with isolated axSpA with no comorbidities. C11 had two patients 
with atrial fibrillation, one of whom also had Parkinson’s disease. C12 to C15 contained only one 
patient each with the following conditions: chronic sinusitis, blindness or low vision, multiple 
sclerosis, and learning disability. 
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All other clusters were generally dominated by 1 to 2 comorbidities with varying number of 
other less frequent conditions (table 2). C2 (n=40) was predominantly characterised by patients 
with concurrent dyspepsia (94%). Clusters 3, 4 and 5 were similar to each other: C3 (n=84) 
patients most commonly had depression (83%) and anxiety (14%); C4 (n=35) patients frequently 
had fibromyalgia (72%) and irritable bowel syndrome (IBS, 56%); C5 had only 4 patients, all with 
anxiety. Clusters 3 and 5 were combined for further analysis since they both include anxiety and 
would merge in the next clustering (figure 1). 
C6, the largest comorbidity cluster (n=88), was predominantly characterised by hypertension 
(82%) and coronary heart disease (CHD, 24%). C7 (n=38) commonly had osteoporosis (74%) and 
alcohol problems (47%). CHD and other cardiovascular diseases feature in both groups, 
explaining their proximity in figure 1. 
C8 (thyroid disease), C9 (other psychoactive substance misuse) and C10 (asthma) were largely 
unrelated to other clusters and each were dominated by a single disease. 
The fibromyalgia-IBS cluster and thyroid disorders cluster were predominantly female and least 
frequently had positive HLA-B27 status or met criteria for AS (table 3). Patients in the 
hypertension-CHD cluster and alcohol problems-osteoporosis cluster were the oldest and had 
higher prevalence of uveitis. Current NSAID use was lowest among those in the dyspepsia and 
other substance misuse clusters. Current smoking was highest among those with other 
substance misuse and lowest among asthmatics. 
Associations between patient-clusters and outcome measures 
In multivariable models, we found that patients in the depression-anxiety clusters (C3 and C5), 
and fibromyalgia-IBS cluster (C4) reported poorer quality of life, global health, fatigue and 
axSpA-specific indices, compared to patients with isolated axSpA (table 3). For instance, EQ5D 
was lower by 0.25 units in both clusters compared to patients with isolated axSpA. Disease 
 10 
 
activity was higher by 0.9 units in the depression-anxiety cluster and 1.8 units in the 
fibromyalgia-IBS cluster. There were no overall differences in ESR or CRP, except patients with 
concurrent dyspepsia had 0.5mg/dl lower CRP than those with isolated axSpA (P=0.008); this 
was not reproduced in sensitivity analyses with imputed missing data (supplementary table 3). 
Patients in the largest cluster (hypertension-CHD) had statistically similar outcome measures as 
those without comorbidity. Patients in C7 (alcohol problems-osteoporosis) reported worse 
global health and function with similar effect sizes to the depression-anxiety cluster, although 
this was not statistically significant. Patients with other psychoactive substance misuse reported 
significantly worse global health by 1.6 units; they also showed a trend of having higher BASDAI. 
Sensitivity analysis using multiple imputation for missing data produced similar results 
(supplementary table 3). Cluster analysis using only morbidities prevalent in at least two 
patients showed similar clusters (supplementary table 4). 
Discussion 
In this cross-sectional study, we found that comorbidity was common among patients with 
axSpA. Several comorbidity clusters were identified, each with only a small number of 
predominant conditions reflecting the overall low number of conditions among those with 
comorbidity. Depression-anxiety and hypertension-coronary heart disease formed the most 
common disease clusters. All comorbidities within the clusters were compatible with shared 
patho-aetiological mechanisms. Patients in the depression-anxiety clusters and fibromyalgia-IBS 
clusters reported worse quality of life, global health, fatigue, disease activity, pain and 
functional impairment. Our data did not provide evidence that any comorbidity clusters were 
significantly associated with ESR or CRP. 
The prevalence of individual morbidities in this study were consistent with those reported in the 
recent worldwide ASAS-COMOSPA cohort which had similar age and gender distributions, 
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although ASAS-COMOSPA included patients with both axial and peripheral SpA [22]. The 
proportion with at least one comorbidity was higher in our cohort (61% vs 51%), but this is likely 
due to the larger number of conditions we included. Our cohort had a greater proportion of 
current smokers (35% vs 29%), which may explain the higher prevalence of coronary heart 
disease (6% vs 1%). Interestingly, the prevalence of hypertension in our cohort was lower (19% 
vs 34%). ASAS-COMOSPA included single-measurement blood pressure thresholds in their 
definition of hypertension, which may lead to over-diagnosis [23]. Osteoporosis was also less 
common (6% vs 13%), which may be under-documented since a previous study [24] found a 9% 
prevalence of osteoporosis in a subgroup of this cohort (defined by T-score≤-2.5, as was in 
ASAS-COMOSPA). 
Depression and fibromyalgia were not described in ASAS-COMOSPA. The prevalence of 
depression reported in our cohort was very similar to results from a prior meta-analysis in axSpA 
(16% vs 15%) [25]. Fibromyalgia (5%) was likely under-diagnosed, compared to prevalence 
reported using meta-analysis (13%) and found by screening questionnaire in the British Society 
for Rheumatology Biologics Register for AS (21%) [26,27]. Associations between clusters 
dominated by these two conditions and patient-reported outcome measures were similar in 
magnitude to those reported in other studies [25–27,7]. In previous meta-analysis, depression 
was additionally associated with objective measures such as ESR and the Bath AS metrology 
index [25]. Baseline depression has also been shown to reduce treatment response in RA [28] 
but further studies are needed in axSpA. 
The prevalence of conditions included in our study has also been described in the general UK 
population and an RA cohort [3,6]. We cannot directly compare prevalence figures, since these 
studies identified conditions using diagnostic codes; results were nevertheless similar apart 
from the notably higher prevalence of depression in our axSpA cohort (16% compare with 5% in 
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RA and 8% in the UK population). AxSpA is a chronic condition with early age at disease onset, 
which may impact psychological well-being more than diseases that develop in later life. 
Differences in patient characteristics across the comorbidity clusters were consistent with 
existing literature. Both fibromyalgia [29] and thyroid disorders [30] were more prevalent 
among females which, given these clusters were predominantly female, explains the higher 
prevalence of peripheral joint involvement and lower prevalence of radiographic disease and 
HLA-B27 positivity [31]. The prevalence of cardiovascular disease and osteoporosis both 
increase with age, as does the risk of uveitis [32]. 
A key strength of this study was the range and number of comorbidities, selected based on their 
importance in the general population rather than their relationship to the index disease. The 
latter approach is common among studies of comorbidity, many of which include diseases based 
on prevalence or availability of data and may overlook important conditions. We extracted 
comorbidity data from diagnoses documented in clinical notes, which are likely more accurate 
than those obtained from patient-recall or administrative diagnostic codes alone. Several 
sources of clinical information were reviewed to reduce the possibility of missing diagnoses.  
Severe axSpA is likely to increase the risk of depression, and depression is known to impact the 
experience and reporting of pain [25,33]. We cannot draw conclusions on the direction of 
causation due to the cross-sectional design of this study. However, our aim was to identify 
patient-clusters that may benefit from additional management. Our results may have limited 
generalisability to all axSpA cohorts, since this study was conducted at a specialist centre that 
served an area with high levels of deprivation. Since this study used data from each patient’s 
first clinic visit, the numbers using TNF inhibitors was low. This may also explain the low 
prevalence of current NSAID-use; referral may be driven by lack of response to previously 
prescribed, and thus discontinued, NSAIDs. We did not have data on cumulative NSAID 
exposure, which would be more relevant for comorbidities. We did not correct for multiple 
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testing since all outcomes measured the same underlying construct - disease severity - and were 
not completely independent. Although consistent associations across several outcomes are 
reassuring, care should be taken when interpreting isolated significant results (such as the 
association between global health and other substance misuse). Lastly, certain objective 
outcome measures were lacking in this study: most of our data were collected from before the 
introduction of the AS disease activity score (ASDAS), and BASMI was not routinely measured. 
We also did not have any measure of severity for each comorbid condition. 
In other chronic rheumatic conditions, such as gout, cluster analyses of comorbidities included 
conditions that could be considered part of the disease process [17]. For instance dyslipidaemia, 
hypertension, obesity and hyperuricaemia are components of the metabolic disease pathway. 
Including these high-prevalence disease features/manifestations would dominate and impair 
clustering of rarer comorbidities. This was an additional reason for excluding extra-articular 
manifestations from our analyses. However, it would be interesting to repeat our analysis in 
older axSpA cohorts with a higher comorbidity burden. 
In conclusion, comorbidity is common among patients with axSpA which was frequently driven 
by concurrent cardiovascular and mental-health disorders. Patients with comorbid depression-
anxiety and fibromyalgia-IBS reported worse overall quality of life, global health, fatigue and 
axSpA disease activity. These results highlight the importance of comorbidities and will inform 
healthcare professionals in the delivery more patient-centred management of axSpA. 
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Table 1. Patient and disease characteristics of patients according to whether 
they have isolated axial spondyloarthritis (axSpA) or axSpA with comorbidities. 
 Isolated axSpA  
n=164 
axSpA with 
comorbidities 
n=255 
P-value 
Age, mean (SD) years  40.0 (12.9) 49.0 (14.1) <0.001 
Male  114 (70%) 177 (69%) 0.980 
Modified New York 
criteria for AS 
135 (82%) 210 (82%) 0.990 
HLA-B27 positive* 66 (62%) 92 (56%) 0.340 
Age at symptom 
onset, mean (SD) 
years 
25.7 (0.8) 28.8 (0.8) 0.008 
Symptom duration, 
median (IQR) years 
10.6 (3.8 to 20.1) 18.9 (8.4 to 30.2) <0.001 
BMI, mean (SD) 27.4 (5.2) 28.7 (5.9) 0.045 
Deprivation index**, 
median (IQR) 
2.0 (1.0 to 6.0) 2.0 (1.0 to 5.0) 0.290 
Current smoker 53 (34%) 84 (35%) 0.450 
Ex-smoker 23 (15%) 46 (19%) 
Never smoked 78 (51%) 108 (45%) 
NSAIDs 31 (19%) 40 (16%) 0.392 
Peripheral joint 
involvement 
40 (26%) 73 (30%) 0.480 
Uveitis 39 (25%) 61 (24%) 0.880 
Psoriasis 33 (21%) 40 (16%) 0.180 
IBD 19 (12%) 21 (8%) 0.190 
Disease severity measures: 
EuroQoL, median 
(IQR) 
0.6 (0.1 to 0.8) 0.5 (-0.02 to 0.7) <0.001 
Global health, median 
(IQR) 
4.8 (2.3 to 6.4) 5.2 (3.5 to 7.1) 0.005 
Fatigue, median (IQR) 5.1 (3.0 to 7.1) 6.3 (3.8 to 7.7) 0.021 
BASDAI, median (IQR) 5.6 (3.6 to 7.2) 6.4 (3.9 to 8.1) 0.011 
Spinal pain, median 
(IQR) 
6.0 (3.0 to 8.0) 7.0 (4.0 to 8.0) 0.029 
BASFI, median (IQR) 4.5 (2.2 to 6.7) 6.8 (4.1 to 8.4) <0.001 
ESR (mm/hr) 10.0 (5.0 to 27.0) 13.0 (5.0 to 29.0) 0.067 
CRP (mg/L) 4.0 (1.0 to 17.0) 5.0 (1.0 to 12.0) 0.800 
*HLA-B27 available for 269 patients. 
**Index of multiple deprivation deciles, with 1 representing the top 10% most 
deprived areas and 10 the most affluent. 
Fatigue and global health were single-question visual analogue scales, ranging 
from 0 (worst) to 10 (best). 
EuroQoL, 5-domain quality of life measure; BASDAI, Bath AS disease activity index; 
BASFI, Bath AS Functional index. 
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Table 2. Prevalence of comorbidities in each of 11 patient clusters with more than 1 patient. 
Cluster 1 2 3 4 5 6 7 8 9 10 11 
Number of patients 164 31 50 18 4 88 19 9 16 14 2 
Hypertension   1 (2) 3 (17)  72 (82) 4 (21) 1 (11)    
Depression  3 (10) 42 (84) 4 (22)  15 (17)   1 (6) 1 (7)  
Anxiety and other neuroses  2 (6) 7 (14)  4 (100) 2 (2)      
Schizophrenia or bipolar      3 (3)   1 (6) 1 (7)  
Osteoporosis  1 (3) 5 (10)    14 (74)   1 (7)  
Alcohol problems  1 (3) 1 (2) 1 (6)  6 (7) 9 (47)     
Other psychoactive substance 
misuse 
     1 (1) 1 (5)  16 (100)   
Chronic liver disease    1 (6)  1 (1) 1 (5)     
Viral hepatitis   1 (2)   1 (2)   1 (6)   
Migraine   6 (12)     1 (11)  1 (7)  
Epilepsy*  1 (3) 3 (6)       1 (7)  
Thyroid disorders   1 (2)   3 (3)  9 (100)    
Diabetes   4 (8)   15 (17) 2 (11)     
Atrial fibrillation      3 (3)     2 (100) 
Coronary heart disease   1 (2)   21 (24) 1 (5)   1 (7)  
Heart failure      2 (2) 1 (5)     
Stroke and TIA   1 (2)   4 (5) 1 (5)     
Peripheral vessel disease       1 (5)     
COPD   3 (6)   12 (14) 1 (5)     
Asthma*      3 (3) 1 (5)   14 (100)  
Chronic sinusitis      1 (1)      
Prostate disorders      5 (6)      
Fibromyalgia   2 (4) 13 (72) 1 (25) 2 (2)  1 (11)    
Irritable bowel syndrome   1 (2) 10 (56)  3 (3)    1 (7)  
Diverticular disease   1 (2)   4 (5)      
Constipation*   1 (2)   3 (3)      
Cancer**   4 (8)         
Chronic kidney disease  3 (10)    6 (7) 1 (5)     
Dyspepsia*  29 (94) 1 (2) 3 (17)     2 (13)   
Glaucoma      13 (15)      
Parkinson's disease           1 (50) 
*Currently treated. **Cancer diagnoses in the past 5 years. Cells with zero prevalence were left empty for clarity. Bold text highlights dominant 
morbidities in each cluster. Clusters 12, 13, 14 and 15 were omitted: each had only 1 patient (chronic sinusitis, blind or low vision, multiple sclerosis, and 
learning disability). TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary diseases. 
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Table 3. Differences in baseline characteristics compared between each comorbidity cluster and axial spondyloarthritis patients with no comorbidity.  
Cluster 1 2 3 and 5 4 6 7 8 9 10 11 to 15 
Disease(s) Isolated 
axSpA 
Dyspepsia Anxiety 
and/or 
depression 
Fibromyalgia 
and/or IBS 
Hypertension 
and/or CHD 
Alcohol 
problems 
and/or 
osteoporosis 
Thyroid Other 
substance 
misuse 
Asthma Other rare 
conditions 
n 164 31 54 18 88 19 9 16 14 6 
Age, years  40.0 (12.9) 47.9 (13.8) 44.1 (11.1) 45.9 (10.6) 56.5 (12.2) 58.0 (8.6) 50.6 (14.7) 31.6 (8.1) 37.7 (12.0) 38.3 (19.4) 
Male  114 (70%) 21 (68%) 36 (67%) 7 (39%) 64 (73%) 16 (84%) 2 (22%) 16 (100%) 9 (64%) 6 (100%) 
Modified New 
York criteria for 
AS 
135 (82%) 26 (84%) 41 (76%) 12 (67%) 81 (92%) 15 (79%) 5 (56%) 14 (88%) 11 (79%) 5 (83%) 
HLA-B27 
positive* 
66 (62%) 8 (44%) 17 (47%) 6 (43%) 31 (66%) 7 (70%) 2 (33%) 9 (64%) 6 (50%) 6 (100%) 
BMI 27.4 (5.2) 28.2 (4.6) 29.2 (6.3) 29.7 (8.9) 29.2 (5.7) 30.0 (4.7) 28.4 (2.2) 24.4 (5.0) 29.9 (5.8) 24.5 (6.0) 
Deprivation 
index** 
2.0 (1.0, 
6.0) 
2.0 (1.0, 
5.0) 
2.0 (1.0, 
4.0) 
1.5 (1.0, 
6.0) 
2.0 (1.0, 
5.0) 
5.0 (1.0, 
6.0) 
3.5 (1.0, 
7.5) 
1.5 (1.0, 
4.0) 
1.0 (1.0, 5.0) 3.5 (1.0, 7.0) 
Smoking Current 53 (34%) 12 (44%) 23 (43%) 4 (25%) 22 (27%) 6 (33%) 1 (13%) 15 (94%) 1 (8%) 0 
Ex 23 (15%) 5 (19%) 8 (15%) 4 (25%) 22 (27%) 4 (22%) 1 (13%) 0 1 (8%) 1 (20%) 
Never 78 (51%) 10 (37%) 22 (42%) 8 (50%) 39 (47%) 8 (44%) 6 (75%) 1 (6%) 10 (83%) 4 (80%) 
NSAIDS 31 (19%) 2 (6%) 12 (22%) 3 (17%) 13 (15%) 4 (21%) 2 (22%) 1 (6%) 2 (14%) 1 (17%) 
Peripheral joint 
involvement 
40 (26%) 10 (34%) 15 (28%) 7 (41%) 19 (23%) 7 (37%) 4 (44%) 3 (20%) 6 (43%) 2 (33%) 
Uveitis 39 (25%) 4 (14%) 6 (11%) 6 (35%) 33 (38%) 8 (42%) 1 (11%) 1 (6%) 2 (14%) 0 
Psoriasis 33 (21%) 5 (17%) 11 (21%) 2 (12%) 12 (14%) 2 (11%) 3 (33%) 3 (19%) 2 (14%) 0 
IBD 19 (12%) 3 (10%) 5 (9%) 3 (18%) 7 (8%) 1 (5%) 0 0 1 (7%) 1 (17%) 
Data shown as mean (SD), median (interquartile range) or n (%). 
*HLA-B27 available for 269 patients. 
**Index of multiple deprivation deciles, with 1 representing the top 10% most deprived areas and 10 the most affluent. 
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Table 4. Differences in outcome measures compared between each comorbidity cluster and axial spondyloarthritis patients with no comorbidity.  
Cluster 1 2 3 and 5 4 6 7 8 9 10 11 to 15 
Disease(s) Isolated 
axSpA 
Dyspepsia Anxiety 
and/or 
depression 
Fibromyalgia 
and/or IBS 
Hypertension 
and/or CHD 
Alcohol 
problems 
and/or 
osteoporosis 
Thyroid Other 
substance 
misuse 
Asthma Other rare 
conditions 
n 164 31 54 18 88 19 9 16 14 6 
EuroQoL reference -0.07  
(-0.25, 0.10) 
-0.25  
(-0.37, -0.12) 
-0.25  
(-0.47, -0.03) 
-0.03 
(-0.16, 0.10) 
0.06  
(-0.22, 0.33) 
0.14  
(-0.19, 0.46) 
-0.20  
(-0.41, 0.02) 
-0.07  
(-0.37, 0.23) 
-0.15  
(-0.57, 0.27) 
Global 
health 
reference 0.1  
(-1.0, 1.3) 
0.9  
(0.1, 1.7) 
1.5  
(0.01, 2.9) 
0.3  
(-0.5, 1.2) 
1.4  
(-0.4, 3.3) 
0.9  
(-1.2, 3.0) 
1.5  
(0.1, 2.9) 
0.7  
(-1.2, 2.7) 
0.7  
(-2.0, 3.4) 
Fatigue reference 0.7  
(-0.6, 1.9) 
1.1 
(0.2, 2.0) 
1.9  
(0.3, 3.5) 
0.6  
(-0.3, 1.5) 
0.2  
(-1.8, 2.2) 
-0.8  
(-3.1, 1.5) 
0.3  
(-1.2, 1.9) 
-0.5  
(-2.6, 1.6) 
-0.02  
(-3.0, 2.9) 
BASDAI reference -0.5 
(-1.6, 0.7) 
0.9  
(0.1, 1.8) 
1.8  
(0.4, 3.3) 
0.4  
(-0.5, 1.2) 
-0.2  
(-2.0, 1.6) 
-1.1  
(-3.3, 1.0) 
1.2  
(-0.1, 2.5) 
0.6  
(-1.3, 2.6) 
1.7  
(-1.0, 4.5) 
Spinal 
pain 
reference -0.6  
(-1.9, 0.7) 
1.2  
(0.3, 2.2) 
2.3  
(0.6, 4.0) 
0.4  
(-0.6, 1.5) 
0.3  
(-1.8, 2.3) 
0.4  
(-2.1, 2.9) 
0.8  
(-0.8, 2.4) 
-0.2  
(-2.7, 2.2) 
1.8  
(-1.4, 5.0) 
BASFI reference -0.6  
(-1.9, 0.6) 
1.9  
(1.0, 2.9) 
2.3  
(0.8, 3.9) 
0.7  
(-0.3, 1.7) 
1.7  
(-0.3, 3.7) 
-0.5  
(-3.0, 2.1) 
0.7  
(-0.7, 2.2) 
1.0  
(-1.6, 3.5) 
1.8  
(-1.1, 4.8) 
ESR* reference -0.34  
(-0.84, 0.15) 
-0.02  
(-0.40, 0.35) 
-0.26  
(-0.91, 0.38) 
-0.26  
(-0.64, 0.11) 
-0.02  
(-0.78, 0.74) 
-0.51  
(-1.47, 0.45) 
0.35  
(-0.25, 0.95) 
-0.42  
(-1.30, 0.46) 
-0.07  
(-1.30, 1.16) 
CRP* reference -0.80  
(-1.38, -0.21) 
-0.04  
(-0.49, 0.41) 
-0.05  
(-0.82, 0.72) 
-0.38  
(-0.83, 0.07) 
-0.53  
(-1.49, 0.42) 
-0.02  
(-1.17, 1.13) 
-0.13  
(-0.85, 0.59) 
-0.49  
(-1.54, 0.55) 
-0.21  
(-1.68, 1.26) 
Data shown as regression coefficients (95% confidence interval). For EuroQol, higher values indicate better quality of life (e.g. cluster 4 had 0.25-unit poorer QoL). For all 
other measures, higher values indicate more severe disease (e.g. cluster 4 had 1.5-unit poorer global health). 
Coefficients derived from models using each outcome measure as independent variable, and cluster as a dummy variable with isolated axSpA as the reference group. 
Models adjusted for age, gender, symptom duration, deprivation, current NSAID-use and smoking status. 
Global health and fatigue were measured by single-item questions with 0 as best/no fatigue and 10 as worst.  
*ESR and CRP were log-transformed using Ln(ESR) and Ln(CRP+1).  
EuroQoL, 5-domain quality of life measure; BASDAI, Bath AS disease activity index; BASFI, Bath AS Functional index; IBS, irritable bowel syndrome; CHD, coronary heart 
disease. 
 
